Exhibiting at Asia Fruit Logistica 2025

Shanghai Landcent Biotechnology Co., Ltd. is a globally recognized HealthTech and biotechnology enterprise specializing in the development and production of vector control and malaria prevention solutions. Headquartered in Songjiang District, Shanghai, the company plays a pivotal role in global public health initiatives, particularly in regions affected by vector-borne diseases such as malaria, dengue, and Zika virus.

Core Business

Landcent’s core business is centered around research, innovation, and mass production of public health vector control products. As a mission-driven organization, the company develops and supplies WHO-compliant long-lasting insecticidal nets (LLINs), biopesticides, and novel pharmaceutical formulations for disease prevention and control.

The company operates with a dual objective: to contribute to global health impact while advancing proprietary technologies in public health product innovation.

Product and Service Offerings

Shanghai Landcent Biotechnology’s product portfolio is focused on the following core categories:

• Long-Lasting Insecticidal Nets (LLINs)

  • Neonet™: WHO-prequalified net treated with pyrethroid insecticides
  • Neonet NG™: Next-generation LLIN with dual-insecticide formulation for resistance management

• Malaria Prevention Solutions

  • Codispaq™: Pediatric chewable anti-malarial medication designed for simplified dosing in endemic regions, particularly for infants and children

• Biopesticides and Vector Control Agents

  • Bacitin: A bio-larvicide derived from Bacillus thuringiensis israelensis (BTI) to target mosquito larvae in water bodies

• Traditional Chinese Medicine (TCM) Extracts

  • Herbal active ingredients researched and standardized for integration into infectious disease control protocols

Specialization and Unique Selling Proposition (USP)

Landcent stands at the intersection of biotechnology and global health with a highly specialized product pipeline:

• One of the few companies with WHO-prequalified LLINs
• Focus on pediatric and infant-safe malaria prevention medications
• Integration of traditional medicine with modern biotech platforms
• Participation in global health partnerships (with NGOs, WHO, UN procurement agencies)
• Advanced field validation studies in Africa and Asia

Its competitive edge lies in high-efficacy, cost-efficient innovations that address the evolving challenges of insecticide resistance and treatment access in vulnerable populations.

Financial Insights

While Landcent does not publicly disclose detailed financial statements, reports from global public health financing bodies indicate:

• Multi-year procurement contracts with agencies like UNICEF, The Global Fund, and WHO
• Estimated annual revenue exceeding USD 20 million, primarily from international health partnerships
• Heavy investment in R&D (approx. 10–15% of revenue), particularly in LLINs and pediatric pharmaceuticals

These insights underscore the company’s sustainable revenue base and commitment to innovation.

Shipment Records

Based on procurement records and NGO transparency data:

• Landcent has supplied over 25 million LLINs across sub-Saharan Africa, South Asia, and Latin America
• Regular consignments to countries such as Nigeria, Uganda, Kenya, India, and Myanmar
• WHO and donor-funded agencies cite Landcent as a preferred vendor for field-tested, impact-driven vector control tools

Target Market

Landcent serves a unique set of public health-focused clients, including:

• Government Ministries of Health in malaria-endemic countries
• Global procurement bodies (UNICEF, WHO, Global Fund)
• NGOs and public health organizations (MSF, Malaria Consortium)
• Humanitarian logistics and field hospitals
• Research institutions and public health universities

Their products are designed for wide-scale distribution under donor-funded health campaigns, with logistics tailored for rapid deployment in both rural and urban areas.

Capabilities

• Manufacturing Facilities: GMP-compliant production units for LLINs and pharmaceuticals
• R&D Center: Advanced lab in Shanghai focused on insecticide resistance management and TCM formulation
• Field Evaluation Units: Collaboration with global research hubs for product efficacy testing in real-world conditions
• Regulatory Team: Expertise in dossier development for WHO PQT/VCP and FDA/EMA pathways

Certifications and Compliance

Shanghai Landcent Biotechnology Co., Ltd. complies with stringent international regulatory frameworks:

• WHO Prequalification for Vector Control Products
• GMP Certification for pharmaceutical production
• ISO 13485 (Medical Devices Quality Management System)
• REACH Compliance for chemical formulations
• OECD GLP Standards for product testing

These certifications affirm the company’s operational integrity and facilitate participation in globally financed procurement tenders.

Customer Testimonials

“Landcent's LLINs have proven to be one of the most effective and durable in our distribution campaigns. Their responsiveness and documentation accuracy are key assets.”
— Field Director, NGO Malaria Program, East Africa

“Codispaq simplifies pediatric malaria care significantly. We’ve seen uptake increase where traditional regimens failed.”
— Regional Health Officer, Government of Sierra Leone

Major Achievements

• WHO prequalification of Neonet™ and Neonet NG™, placing Landcent among the top 10 global LLIN suppliers
• Successfully conducted multi-country efficacy trials in collaboration with major universities and health institutes
• Partnered with UNICEF and The Global Fund for emergency net distribution during outbreaks
• Awarded patents for proprietary dual-action insecticidal formulations
• Recognized by WHO Vector Control Advisory Group (VCAG) for innovation in next-generation vector tools

Shanghai Landcent Biotechnology Co., Ltd. exemplifies the fusion of science, policy, and mission-driven health innovation. By prioritizing accessibility, efficacy, and compliance, the company continues to expand its role as a trusted global partner in the fight against vector-borne diseases.